(Q36484155)

14 August 2017

1 reference

title

Systemic sclerosis: hypothesis-driven treatment strategies (English)

1 reference

14 August 2017

Christina Charles

1

1 reference

14 August 2017

Philip Clements

series ordinal

2

1 reference

14 August 2017

Daniel E Furst

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

367

1 reference

14 August 2017

issue

9523

1 reference

14 August 2017

page(s)

1683-1691

1 reference

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Scleroderma--clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Treatment of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Factors predicting development of renal involvement in progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjögren's syndrome and progressive systemic sclerosis: a question of disease relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Microchimerism and scleroderma: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Microchimerism and HLA relationships of pregnancy: implications for autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Microchimerism and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Lack of evidence of foetal microchimerism in female Spanish patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

MCMV induces neointima in IFN-gammaR-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Occupational exposure to crystalline silica and autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Pathogenesis of fibrosis: role of TGF-beta and CTGF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Transforming growth factor-beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-delta, and p38.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Oligoclonal T cell expansion in the skin of patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Targeting mediators of vascular injury in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Systemic sclerosis. A vascular perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Treatment of Raynaud's phenomenon: new insights and developments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Increased alpha 1(I) procollagen gene expression in tight skin (TSK) mice myocardial fibroblasts is due to a reduced interaction of a negative regulatory sequence with AP-1 transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2(I)-collagen (COL1A2) transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

The CREB constitutive activation domain interacts with TATA-binding protein-associated factor 110 (TAF110) through specific hydrophobic residues in one of the three subdomains required for both activation and TAF110 binding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

The two activation domains of the CCAAT-binding factor CBF interact with the dTAFII110 component of the Drosophila TFIID complex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Cloning and characterization of hcKrox, a transcriptional regulator of extracellular matrix gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Deficient Smad7 expression: a putative molecular defect in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

ANTIFIBROTIC THERAPY WITH POTABA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Treatment of systemic sclerosis with D-penicillamine. A new method of observing the effects of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Cyclofenil treatment of scleroderma--a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Prostanoid therapy for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Relaxins: lessons and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968737-0

7 January 2021

10.1016/S0140-6736(06)68737-0

Identifiers

DOI

1 reference

14 August 2017

1 reference